Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2016 - 2025)

Cumberland Pharmaceuticals' Capital Expenditures history spans 16 years, with the latest figure at -$1.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 100.04% year-over-year to -$1.0; the TTM value through Dec 2025 reached $97903.0, up 47.31%, while the annual FY2025 figure was $97903.0, 47.31% up from the prior year.
  • Capital Expenditures for Q4 2025 was -$1.0 at Cumberland Pharmaceuticals, down from $23788.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $137255.0 in Q2 2022 and bottomed at -$153528.0 in Q4 2022.
  • The 5-year median for Capital Expenditures is $23788.0 (2025), against an average of $28076.7.
  • The largest YoY upside for Capital Expenditures was 810.6% in 2022 against a maximum downside of 1797.0% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $9047.0 in 2021, then tumbled by 1797.0% to -$153528.0 in 2022, then soared by 169.86% to $107260.0 in 2023, then crashed by 97.87% to $2283.0 in 2024, then tumbled by 100.04% to -$1.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Capital Expenditures are -$1.0 (Q4 2025), $23788.0 (Q3 2025), and $26486.0 (Q2 2025).